Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis

Based on a large cohort of clinical studies involving a total of 8024 patients and reporting the effects of HER4 on breast cancer prognosis, we conducted the first meta-analysis and review of this type. We identified 26 studies published between 1985 and 2016 and assessed the prognostic value of HER4 in breast cancer by either real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR, for mRNA levels) or immunohistochemistry (IHC, for protein levels). Elevated expression of HER4 was significantly associated with longer relapse-free survival (RFS) (HR = 0.63; CI: 0.48−0.83; P = 0.001, random effects). Further subgroup analysis showed that our results were stable irrespective of subtype [Luminal: HR = 0.40, CI: 0.30−0.53, P < 0.001, fixed effects; triple negative breast cancer (TNBC): HR = 0.49, CI: 0.26−0.90, P = 0.02, fixed effects; and HER2-positive: HR = 0.53, CI: 0.40−0.71, P < 0.001, fixed effects]. Cytoplasmic HER4 was more effective than nuclear HER4 (HR = 0.74, CI: 0.60−0.92, P = 0.007, fixed effects) for predicting RFS. HER4 was also found to be a favorable prognostic marker for overall survival (OS) among patients with non-TNBC in the subgroup analysis (Luminal: HR = 0.71, CI: 0.52−0.95, P = 0.023, fixed effects; HER2-positive: HR = 0.48, CI: 0.26−0.89, P = 0.020, fixed effects).

[1]  H. Iwase,et al.  Association of ErbB1–4 expression in invasive breast cancer with clinicopathological characteristics and prognosis , 2012, Breast Cancer.

[2]  L. Caskey,et al.  HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells , 2001, Molecular and Cellular Biology.

[3]  N. Kanomata,et al.  Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab , 2015, Breast Cancer.

[4]  H. Earp,et al.  The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells , 2005, Breast Cancer Research.

[5]  J. Bartlett,et al.  The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. , 2006, Cancer research.

[6]  A. Walch,et al.  PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas , 2007, British Journal of Cancer.

[7]  A. Walch,et al.  Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients , 2008, British Journal of Cancer.

[8]  L. Marrero,et al.  Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. , 2005, The Journal of biological chemistry.

[9]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[10]  B. Fingleton,et al.  Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor. , 2007, Cancer research.

[11]  M. Ando,et al.  Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Thor,et al.  The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. , 2008, Cancer research.

[13]  J. Jakić-Razumović,et al.  Significance of epidermal growth factor receptor expression in breast cancer , 2011, Medical oncology.

[14]  F. Révillion,et al.  Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Arvind K Pandey,et al.  Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. , 2006, Cancer research.

[16]  D. Stern.  ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[17]  N. Bundred,et al.  Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In situ of the Breast , 2005, Clinical Cancer Research.

[18]  Erez M. Bublil,et al.  The EGF receptor family : spearheading a merger of signaling and therapeutics , 2007 .

[19]  J. Kjems,et al.  Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo , 2013, British Journal of Cancer.

[20]  Xiaoming Deng,et al.  Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. , 2003, Cancer research.

[21]  A. Thor,et al.  Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. , 2009, The American journal of pathology.

[22]  J. Isola,et al.  Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. , 2005, Cancer research.

[23]  A. Harris,et al.  Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. , 2014, Oncotarget.

[24]  Jorma Isola,et al.  Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. , 2005, Molecular biology of the cell.

[25]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[26]  Frank E. Jones,et al.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone , 2004, The Journal of cell biology.

[27]  Yu Wang,et al.  Response to: Practical methods for incorporating summary time-to-event data into meta-analysis , 2013, Trials.

[28]  J. Bartlett,et al.  HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4 , 2006, Breast Cancer Research.

[29]  M. Klagsbrun,et al.  A Natural ErbB4 Isoform That Does Not Activate Phosphoinositide 3-Kinase Mediates Proliferation but Not Survival or Chemotaxis* , 2000, The Journal of Biological Chemistry.

[30]  W. Henrich,et al.  Epidermal growth factor receptor changes during breast cancer metastasis. , 2006, Anticancer research.

[31]  S. Wiseman,et al.  Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival , 2005, Cancer.

[32]  A. Laenkholm,et al.  Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors , 2009, Breast Cancer Research.

[33]  O. Ortmann,et al.  The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients , 2013, BMC Cancer.

[34]  H. P. Fell,et al.  The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells* , 1996, The Journal of Biological Chemistry.

[35]  J. Sterne,et al.  Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. , 2001, Journal of clinical epidemiology.

[36]  Colin G. Johnson,et al.  The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer , 2010, Breast Cancer Research and Treatment.

[37]  I. Bièche,et al.  Prognostic value of ERBB family mRNA expression in breast carcinomas , 2003, International journal of cancer.

[38]  L. Marrero,et al.  Presenilin-dependent γ-Secretase Processing Regulates Multiple ERBB4/HER4 Activities* , 2005, Journal of Biological Chemistry.

[39]  Melissa A. Sandahl,et al.  Heregulin-Dependent Delay in Mitotic Progression Requires HER4 and BRCA1 , 2006, Molecular and Cellular Biology.

[40]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  I. Ellis,et al.  Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts , 2013, British Journal of Cancer.

[42]  Arndt Hartmann,et al.  Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients , 2008, Breast Cancer Research.

[43]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[44]  J. Nesland,et al.  EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.

[45]  Aiko Sueta,et al.  The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer , 2014, Oncotarget.

[46]  V. Cogliano.  International Agency for Research on Cancer (IARC) , 2018, The Grants Register 2019.